약독화된 박테리아와 IL-1β를 유효성분으로 포함하는 암 예방 및 치료용 조성물
    31.
    发明公开
    약독화된 박테리아와 IL-1β를 유효성분으로 포함하는 암 예방 및 치료용 조성물 有权
    包含衰老的生物细菌和IL-1β的药物组合物用于预防或治疗癌症

    公开(公告)号:KR1020140107954A

    公开(公告)日:2014-09-05

    申请号:KR1020130022219

    申请日:2013-02-28

    CPC classification number: Y02A50/481 A61K38/20

    Abstract: Provided in the present invention is a composition to prevent and treat cancer which comprises attenuated salmonella species strain and interleukin-1β (IL-1β) to increase an anticancer effect of attenuated anaerobic bacteria for treatment. According to an embodiment of the present invention formed like the same, a composition to prevent and treat cancer, and a treatment method using the same increasing the anticancer effect of the attenuated salmonella strain can be provided.

    Abstract translation: 本发明提供了一种预防和治疗癌症的组合物,其包括减毒沙门氏菌菌株和白细胞介素-1β(IL-1β),以增加减毒厌氧细菌治疗的抗癌作用。 根据本发明的一个实施方案,可以提供预防和治疗癌症的组合物,以及使用该组合物增加减毒沙门氏菌菌株的抗癌作用的治疗方法。

    세포 내 병원성 세균 감염증 예방 또는 치료용 조성물
    32.
    发明公开
    세포 내 병원성 세균 감염증 예방 또는 치료용 조성물 有权
    预防或治疗细菌性致病菌细菌感染的组合物

    公开(公告)号:KR1020140106124A

    公开(公告)日:2014-09-03

    申请号:KR1020130020258

    申请日:2013-02-26

    Inventor: 최흥식 최현일

    CPC classification number: Y02A50/403 Y02A50/478 A61K48/00 C12N15/11

    Abstract: The present invention relates to a novel method capable of treating intracellular pathogenic bacteria infection by serum iron homeostasis control. The present invention provides a composition comprising ERRγ protein expression or an activity inhibitor, capable of effectively treating intracellular pathogenic bacteria infection as an active ingredient to prevent or treat intracellular pathogenic bacteria infection.

    Abstract translation: 本发明涉及能够通过血清铁稳态控制来治疗细胞内致病菌感染的新方法。 本发明提供了包含ERRγ蛋白质表达或活性抑制剂的组合物,其能够有效地治疗细胞内致病菌感染作为活性成分,以预防或治疗细胞内致病菌感染。

    신규 박테리아 용해 단백질 및 그의 용도
    34.
    发明公开
    신규 박테리아 용해 단백질 및 그의 용도 有权
    新型细菌蛋白质及其用途

    公开(公告)号:KR1020130060605A

    公开(公告)日:2013-06-10

    申请号:KR1020110126747

    申请日:2011-11-30

    CPC classification number: C07K14/255 A61K47/42 A61K47/62 C12N15/63

    Abstract: PURPOSE: A novel polypeptide and a polynucleotide encoding the same are provided to properly control bacterial lysis and to effectively release a drug transferred by therapeutic bacteria to a lesion. CONSTITUTION: A polypeptide has holin non-dependent cell lysis activities with 70% or more homology with an amino acid sequence of sequence number 3. The polypeptide has 70% or more homology with an amino acid sequence of sequence number 1. A polynucleotide encodes the polypeptide. A vector contains the polynucleotide. A host cell is transformed with the vector. [Reference numerals] (AA) pLT1::ORF1, Control group; (BB) pLT1::ORF1, Induced; (CC,FF,II,LL,OO,RR) Time(hours); (DD) pLT35-1, Control group; (EE) pLT35-1, Induced; (GG) pLT1::ORF2, Control group; (HH) pLT1::ORF2, Induced; (JJ) pLT33, Control group; (KK) pLT33, Induced; (MM) pLT1::ORF3, Control group; (NN) pLT1::ORF3, Induced; (PP) pLT34, Control group; (QQ) pLT34, Induced

    Abstract translation: 目的:提供新的多肽和编码该多肽的多核苷酸以适当地控制细菌裂解并有效地将由治疗性细菌转移的药物释放到病变处。 构成:多肽具有与序列号3的氨基酸序列具有70%或更高同源性的完全非依赖性细胞裂解活性。多肽与序列号1的氨基酸序列具有70%或更高的同源性。多核苷酸编码 多肽。 载体含有多核苷酸。 用载体转化宿主细胞。 (标号)(AA)pLT1 :: ORF1,对照组; (BB)pLT1 :: ORF1,诱导; (CC,FF,II,LL,OO,RR)时间(小时); (DD)pLT35-1,对照组; (EE)pLT35-1,诱导; (GG)pLT1 :: ORF2,对照组; (HH)pLT1 :: ORF2,诱导; (JJ)pLT33,对照组; (KK)pLT33,诱导; (MM)pLT1 :: ORF3,对照组; (NN)pLT1 :: ORF3,诱导; (PP)pLT34,对照组; (QQ)pLT34,诱导

    경구용 백신 운반을 위한 미세입자 및 이들의 제조방법
    35.
    发明授权
    경구용 백신 운반을 위한 미세입자 및 이들의 제조방법 失效
    用于递送口服疫苗的微粒及其制造方法

    公开(公告)号:KR100664466B1

    公开(公告)日:2007-01-04

    申请号:KR1020040028800

    申请日:2004-04-26

    CPC classification number: Y02A50/481

    Abstract: 본 발명은 세포외 다당류를 이용한 백신 운반용 미세입자에 관한 것으로, 보다 상세하게는 GFP 발현
    Salmonella typhimurium 균체를 항원모델로 하고 이들을 함유하는 세포외 다당류를 사용하여 제조한 경구용 백신 운반용 미세입자 및 그 제조방법에 관한 것이다.
    약물운반 시스템, 미세입자, 리포좀, 다당류, β-1,3-글루칸, 커들란-설페이트, O-팔미토일 커들란-설페이트, O-팔미토일 스클레로글루칸-설페이트

    비브리오 패혈증균의 독력인자 발현을 조절하는범독력인자 발현 조절인자인 cAMP 수용체 단백질 및아데닐레이트 사이클라아제
    38.
    发明公开
    비브리오 패혈증균의 독력인자 발현을 조절하는범독력인자 발현 조절인자인 cAMP 수용체 단백질 및아데닐레이트 사이클라아제 失效
    cAMP受体蛋白和VIBRIO VULNIFICUS的ADENYLATE CYCLASE作为全球血液调节因子调节VIRULENCE表达

    公开(公告)号:KR1020040092147A

    公开(公告)日:2004-11-03

    申请号:KR1020030026365

    申请日:2003-04-25

    CPC classification number: A61K39/107 A61K2039/52

    Abstract: PURPOSE: cAMP receptor protein and adenylate cyclase of Vibrio vulnificus as global virulence regulators to regulate virulence expression are provided. Therefore, the host cell is protected from infection of Vibrio vulnificus by deleting genes encoding the cAMP receptor protein and adenylate cyclase. CONSTITUTION: The crp gene encoding the cAMP receptor protein(CRP) of Vibrio vulnificus to regulate virulence expression has the nucleotide sequence of SEQ ID NO:1, wherein the cAMP receptor protein(CRP) of Vibrio vulnificus has the amino acid sequence of SEQ ID NO:2. The cya gene encoding the adenylate cyclase of Vibrio vulnificus which binds to the CRP to activate the CRP has the nucleotide sequence of SEQ ID NO:3, wherein the adenylate cyclase of Vibrio vulnificus has the amino acid sequence of SEQ ID NO:4.

    Abstract translation: 目的:提供创伤弧菌的cAMP受体蛋白和腺苷酸环化酶,作为调控毒力表达的全局毒力调节因子。 因此,通过删除编码cAMP受体蛋白质和腺苷酸环化酶的基因,保护宿主细胞免受创伤弧菌的感染。 构成:编码创伤弧菌的cAMP受体蛋白(CRP)的crp基因用于调节毒力表达具有SEQ ID NO:1的核苷酸序列,其中创伤弧菌的cAMP受体蛋白(CRP)具有SEQ ID NO:1的氨基酸序列 NO:2。 结合CRP以激活CRP的编码创伤弧菌的腺苷酸环化酶的cya基因具有SEQ ID NO:3的核苷酸序列,其中创伤弧菌的腺苷酸环化酶具有SEQ ID NO:4的氨基酸序列。

Patent Agency Ranking